Pyxis Oncology reports 36% cORR, 6.2-month mPFS, 79% 12-month OS probability
Pyxis Oncology reported a 36% confirmed objective response rate and 6.2-month median PFS for MICVO in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.